These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 3259680)
1. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring. Koebl H; Tatra G; Bieglmayer C Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680 [TBL] [Abstract][Full Text] [Related]
3. [Comparative studies on the value of acute phase proteins and CA-125 for monitoring patients with ovarian cancer]. Kölbl H; Tatra G; Schieder K; Bieglmayer C Strahlenther Onkol; 1988 Dec; 164(12):724-8. PubMed ID: 2462754 [TBL] [Abstract][Full Text] [Related]
4. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer. Koelbl H; Schieder K; Neunteufel W; Bieglmayer C Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933 [TBL] [Abstract][Full Text] [Related]
5. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors]. Crombach G; Zippel HH; Würz H Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962 [TBL] [Abstract][Full Text] [Related]
6. [Clinical study on the serum carcinoembryonic antigen, immunosuppressive acidic protein and C-reactive protein levels in patients with adult T cell leukemia]. Kumagai E; Ogata M; Maeda Y; Kumagai T; Okajima K; Yamaguchi K; Tanoue S Rinsho Byori; 1989 Jul; 37(7):769-73. PubMed ID: 2607647 [TBL] [Abstract][Full Text] [Related]
7. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer]. Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692 [TBL] [Abstract][Full Text] [Related]
8. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer. Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619 [TBL] [Abstract][Full Text] [Related]
10. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929 [TBL] [Abstract][Full Text] [Related]
11. [Serum CA 125 values and histologic findings at the time of second-look laparotomy in ovarian cancer]. Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H Geburtshilfe Frauenheilkd; 1988 May; 48(5):331-3. PubMed ID: 3165078 [TBL] [Abstract][Full Text] [Related]
12. Role of Ca 125 as tumor marker in ovarian carcinoma. Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052 [TBL] [Abstract][Full Text] [Related]
13. [Inflammatory reaction and laboratory tests: IAP (immunosuppressive acidic protein)]. Sato T; Sakata Y; Tamura K Rinsho Byori; 1990 Mar; 38(3):255-9. PubMed ID: 2190023 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer. Castelli M; Battaglia F; Scambia G; Panici PB; Ferrandina G; Mileo AM; Mancuso S; Ferrini U Oncology; 1991; 48(1):13-7. PubMed ID: 1987493 [TBL] [Abstract][Full Text] [Related]
15. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895 [TBL] [Abstract][Full Text] [Related]
16. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Brakora KA; Lee H; Yusuf R; Sullivan L; Harris A; Colella T; Seiden MV Gynecol Oncol; 2004 May; 93(2):361-5. PubMed ID: 15099946 [TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer. Battaglia F; Scambia G; Panici PB; Castelli M; Ferrandina G; Foti E; Amoroso M; D'Andrea G; Mancuso S Gynecol Oncol; 1994 May; 53(2):176-82. PubMed ID: 8188076 [TBL] [Abstract][Full Text] [Related]
18. [Study on serum levels of immunosuppressive acidic protein (IAP) as a marker of renal cell carcinoma]. Hoshino M; Fuji K; Kataoka K; Inoue K; Higaki Y; Imamura K Hinyokika Kiyo; 1989 Oct; 35(10):1647-52. PubMed ID: 2610170 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer. Crombach G; Zippel HH; Würz H Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535 [TBL] [Abstract][Full Text] [Related]
20. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Jacobs IJ; Oram DH; Bast RC Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]